Actelion hikes dividend ahead of Opsumit regulatory decision

ZURICH Feb 14 (Reuters) - Europe's largest biotech company Actelion said it would hike its dividend by 25 percent as investors wait for a U.S. regulatory decision on its new heart and lung drug, Opsumit, which it hopes will cut its dependency on current mainstay Tracleer.

The group posted a full-year net profit of 303.2 million Swiss francs, compared to a loss of 146.3 million francs a year ago. Analysts in a Reuters poll had forecast net profit of 303 million.

Actelion proposed a 25 percent increase in its dividend to 1.00 franc. (Reporting by Caroline Copley)